Pharmaceutical effluent can run at a COD twenty times stronger than domestic sewage, carrying solvents and active drug compounds that ordinary biological treatment cannot break down. Our pharmaceutical effluent treatment plant is built around that reality, not scaled up from a generic industrial template.
API manufacturing effluent commonly runs at COD levels between 3,000 and over 10,000 mg/L, compared to domestic sewage sitting around 450 to 550 mg/L, roughly twenty times stronger, and that strength comes loaded with solvents, active pharmaceutical ingredients and organic compounds that resist conventional biological breakdown. A pharma ETP manufacturer cannot simply scale up a standard industrial plant and expect it to hold. This is why our pharmaceutical effluent treatment plant is built around advanced oxidation ahead of biological treatment, breaking down recalcitrant API molecules into simpler compounds that a biological stage can actually finish treating, rather than passing that burden downstream where it will not get resolved.
Not every pharma facility needs the same treatment depth, formulation units and bulk API manufacturers generate very different effluent strength and complexity.
Find the Right Treatment Train for Your Facility
AOP breaks down recalcitrant API compounds and improves biodegradability, followed by a biological stage to handle the remaining organic load. Suited to mid-strength effluent from formulation and general pharma manufacturing.
Primary, biological and tertiary stages combined with activated carbon adsorption, built for facilities needing consistent, audit-ready effluent quality beyond basic discharge compliance.
A complete treatment train ending in RO and evaporation, designed for bulk drug and API manufacturers where Zero Liquid Discharge is mandated, engineered as one system rather than retrofitted piecemeal.
Lab analysis identifies COD strength, specific solvents, API compounds and any compounds likely to inhibit biological treatment, before any equipment gets sized.
Screening and equalization buffer flow and concentration swings, common in batch pharmaceutical production, so downstream stages receive a manageable, consistent load.
Ozone or UV/hydrogen peroxide based oxidation breaks down recalcitrant API molecules into simpler organic compounds, reducing toxicity and improving biodegradability ahead of biological treatment.
Aerobic biological treatment handles the organic load that oxidation has made treatable, typically the highest-load stage in terms of COD reduction.
Activated carbon adsorption removes residual organic compounds and trace contaminants, bringing effluent quality within a stronger compliance margin than basic secondary treatment alone.
Water either meets discharge-ready quality for release, or, where ZLD applies, continues through RO and evaporation stages to achieve zero liquid discharge.
This configuration applies across formulation units, bulk drug and API manufacturing, and biotechnology facilities generating effluent with solvents, active compounds or antibiotic residues. Bulk API manufacturers in particular fall under closer regulatory scrutiny, CPCB mandates Zero Liquid Discharge for many API and bulk-drug units, and antibiotic residue in treated discharge has become a flagged public health concern in India's major pharma manufacturing hubs. If your facility falls into this category, or your consent to operate references ZLD, the treatment train needs to be designed around that requirement from day one rather than added on afterward.
COD strength and API complexity are the primary cost drivers, a formulation unit's effluent typically costs less to treat than a bulk API manufacturer running solvent-heavy, high-COD discharge. Advanced oxidation equipment and its ongoing power or reagent consumption adds meaningfully to both capital and operating cost compared to a standard biological ETP, but it is the difference between a plant that actually clears API compounds and one that just moves the problem downstream. If ZLD applies to your facility, RO and evaporation stages represent a significant share of total system cost, one reason we design this in from the start rather than retrofitting it onto an undersized plant later. We size cost after a full effluent characterization, not a flat industrial rate that ignores what pharmaceutical wastewater actually requires.
Active pharmaceutical ingredients and many solvents are specifically designed to resist biological breakdown, that is often a property of the drug compound itself. Advanced oxidation breaks these molecules into simpler compounds before biological treatment, without it, a meaningful share of API load passes through untreated.
CPCB mandates ZLD for many API and bulk-drug manufacturing units, particularly in critically polluted industrial zones. Whether it applies to your specific facility depends on your product category, location and consent to operate, worth confirming with your state pollution control board if you are unsure.
Advanced oxidation combined with tertiary activated carbon polishing specifically targets the antibiotic and API residues that basic secondary treatment leaves behind, this is a regulatory and public health concern that has drawn increasing scrutiny around major pharma manufacturing hubs in India.
Not necessarily, formulation effluent is typically less concentrated than bulk API manufacturing discharge. We size the treatment train to your actual effluent characterization rather than applying bulk-drug-level treatment to every pharma client by default.
Pharmaceutical production often changes product lines over time, we design dosing and treatment capacity with some flexibility for this, and recommend periodic effluent re-characterization if your manufacturing profile changes significantly.
Share your raw water laboratory reports and discharge limits with our senior engineering team.